ES2586328T3 - Factores predisponentes para el tratamiento del cáncer - Google Patents
Factores predisponentes para el tratamiento del cáncer Download PDFInfo
- Publication number
- ES2586328T3 ES2586328T3 ES12754124.1T ES12754124T ES2586328T3 ES 2586328 T3 ES2586328 T3 ES 2586328T3 ES 12754124 T ES12754124 T ES 12754124T ES 2586328 T3 ES2586328 T3 ES 2586328T3
- Authority
- ES
- Spain
- Prior art keywords
- positive
- rituximab
- biomarkers
- psmb1
- cancer treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract description 11
- 238000011282 treatment Methods 0.000 title abstract description 10
- 201000011510 cancer Diseases 0.000 title abstract 3
- 229960004641 rituximab Drugs 0.000 abstract description 17
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 abstract description 15
- 102100025136 Macrosialin Human genes 0.000 abstract description 15
- 101000706678 Homo sapiens Proteasome subunit beta type-1 Proteins 0.000 abstract description 9
- 102100031566 Proteasome subunit beta type-1 Human genes 0.000 abstract description 9
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 abstract description 5
- 229960001467 bortezomib Drugs 0.000 abstract description 4
- 230000004044 response Effects 0.000 abstract description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 description 26
- 230000006872 improvement Effects 0.000 description 12
- 102220519534 Proteasome subunit beta type-1_P11A_mutation Human genes 0.000 description 9
- 239000003550 marker Substances 0.000 description 8
- 230000003325 follicular Effects 0.000 description 6
- 101000735881 Homo sapiens Proteasome subunit beta type-5 Proteins 0.000 description 3
- 102100036127 Proteasome subunit beta type-5 Human genes 0.000 description 3
- 102220634106 Proteasome subunit beta type-5_R24C_mutation Human genes 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 1
- 102220557853 Proteasome subunit beta type-9_R60H_mutation Human genes 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 238000009092 lines of therapy Methods 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
Abstract
Un método de predicción de la respuesta a un tratamiento del cáncer que comprende bortezomib y rituximab en un paciente con cáncer de linfoma no Hodgkin, que comprende: determinar el nivel o la cantidad de un primer factor predisponente en una muestra biológica de dicho paciente, en el que dicho primer factor predisponente es CD68 o el polimorfismo de PSMB1 (P11A); y determinar la presencia o cantidad de un segundo factor predisponente en dicho paciente; en el que CD68 bajo o la presencia del polimorfismo de PSMB1 (P11A) se correlaciona con al menos un resultado positivo, y la presencia, ausencia o cantidad de dicho segundo factor predisponente se correlaciona con al menos un resultado positivo.
Description
5
10
15
20
25
30
35
40
Ciento dos pares de biomarcadores tuvieron una p<0,05 de rangos logarítmicos. De estos, 97 pares tenían una frecuencia de >1 % en la población. Catorce pares mostraron, además, una mejora de PFS de ≥6 meses. En este análisis, se hicieron 1.140 comparaciones por pares (las covariables se aparearon con cada marcador individual para complementar los análisis). Después de la corrección de FDR, 1 par fue significativo (FDR = 0,051). Este par de biomarcadores identificó el 33 % de la población evaluable de biomarcadores con una ventaja de 7,5 meses de PFS cuando se trataron con Vc-R en comparación con rituximab solo (Tabla 4) y una tendencia a una mejor OS (p = 0,055, HR: 0,426 [0,174,1,046], Este par se compone de PSMB1 P11A (heterocigoto C/G) y baja expresión de CD68 definido como 0-50 células teñidas positivamente. A continuación, este par se mencionará como el subgrupo de biomarcadores positivos. El subgrupo de biomarcadores negativos no tiene este par de biomarcadores y tiene un diferente genotipo de PSMB1 y nivel de expresión de CD68.
Tabla 4: Comparación de la PFS y la OS de la población de biomarcadores positivos con la población de biomarcadores negativos
- Biomarcador positivo (N=118)
- Biomarcador negaitivo (N=238) Total (N=356)
- Vc-R
- Rituximab Vc-R Rituximab Vc-R Rituximab
- N
- 57 61 118 120 175 181
- Mediana (meses
- 16.6 9.1 12.5 12.5 13.6 11.3
- PFS
- 95% CI (0.26-0.639) (0.759-1.425) (0.621-1.032)
- Valor-p
- 0.0001 0.8097 0.0855
- HR
- 0.407 1.04 0.801
- Vc-R
- Rituximab Vc-R Rituximab Vc-R Rituximab
- N
- 57 61 118 120 175 181
- Mediana (meses
- NA NA NA NA NA NA
- OS
- 95% CI (0.174-1.046) (0.617-1.658) (0.527-1.239)
- Valor-p
- 0.0550 0.9645 0.3270
- HR
- 0.426 1.011 0.808
- Biomarcador positivo = PSMB heterocigoto P11a y CD68 "baja" par biomarcador, biomarcador negativo = todos los sujetos sin este par, Vc-R = Bortezomib + Rituximab, PFS = supervivencia libre de progresión, OS = supervivencia global, IC = confianza intervalo, HR = cociente de riesgos instantáneos
De manera importante, el subgrupo de biomarcadores positivos (heterocigoto de PSMB1 P11A y baja expresión de CD68) tuvo, además, una velocidad de respuesta total significativamente mejor del 73,7 % para los tratados con Vc-R en comparación con el 47,5 % con R solo (p=0,0077), y un tiempo más largo hasta el siguiente tratamiento (p = 0,0013) y duración del intervalo sin tratamiento (p=0,0017).
Se observaron perfiles AE similares en las poblaciones de biomarcadores positivos y biomarcadores negativos. Se observó una exposición al tratamiento similar en las poblaciones de biomarcadores positivos y de biomarcadores negativos. Los sujetos tratados con rituximab en la población de biomarcadores positivos tuvieron una mediana de la dosis de 2941 mg/m2 en comparación con 2940 mg/m2 en la población de biomarcadores negativos. Los sujetos tratados con Vc-R en la población de biomarcadores positivos tuvieron una mediana de la dosis de 31,1 mg/m2 en comparación con 30 mg/m2 en la población de biomarcadores negativos. Además el número total de dosis, la duración de la exposición, la intensidad de la dosis, la intensidad relativa de dosis y el número máximo de ciclos recibidos mostraron diferencias muy similares.
Los sujetos tratados con bortezomib + rituximab mantuvieron PFS más larga cuando el biomarcador fue positivo y se estratificaron por cualquiera de la puntuación FLIPI, por la carga tumoral, por la puntuación de Ann Arbor, por la edad, por la región, por el sexo y por la raza. En los pacientes con mayor riesgo y mal pronóstico, por ejemplo, alta carga tumoral, medio o alto FLIPI, mayores de 65 años, o con tratamiento previo con rituximab, se observaron mejoras mayores de PFS en pacientes cuando el biomarcador es positivo en comparación a cuando el biomarcador es negativo. La PFS más larga se mantuvo independientemente del tiempo a partir del último tratamiento o el número de tratamientos previos por rituximab previo o el número de tratamientos con rituximab menores o iguales a
2.
Los sujetos tratados con bortezomib + rituximab mantuvieron una supervivencia global más larga cuando el biomarcador fue positivo y se estratificaron por la puntuación de FLIPI, por la carga tumoral, por la puntuación de Ann Arbor, por la edad, por la región, por el sexo y por la raza. Los sujetos tratados con Velcade + rituximab mantuvieron una PFS más larga cuando fueron positivos para CD68 bajo (0-50) y se estratificaron por cualquiera de la puntuación FLIPI, por la carga tumoral, por la puntuación de Ann Arbor, por la edad, por la región, por el sexo y
12
Tabla 6. Pares marcadores significativos
- Marcador A
- Marcador B PFS Vc+R vs. R media meses N Vc+R vs. R Logrank Valor-p FDR
- PSMB5/R24C C/T
- P65 Intensidad de señal citoplasmica <=1+ 27 mo vs. 10.4 mo 16.6 mo mejora 5 vs. 7 0.0439 0.489
- PSMB1/P11A C/G
- 20S % SEÑALCITOPLASMICA POSTIVA: >90 18.9 mo vs. 9.5 mo 9.4 mejora 50 vs50 0.0145 0.447
- PSMB1/P11A C/G
- CD68 Positivo folicular 0-50 16.6 mo vs. 9.1 mo 7.5 mejora 57 vs61 0.0001 0.051
- PSMB1/P11A C/G
- CD68 Positivo peri – folicular: >50 16.6 mo vs. 9.2 mo 7.4 Mo mejora 24 vs28 0.0365 0.471
- PSMB9/R60H G/G
- P65 % TINCIÓN NUCLEAR: >0 16.2 mo vs. 9.5 mo 6.7 mejora 35 vs28 0.0303 0.455
- PSMB5/R24C C/T
- CD68 Positivo folicular 0-50 13.7 mo vs. 7.2 mo 6.5 mo mejora 18 vs21 0.0220 0.447
- HI Tumor BD NO
- CD68 Positivo global 0-50 22.8 mo vs. 16 mo 6.8 mo mejora 64 vs68 0.0177 0.447
- HI Tumor BD NO
- CD68 Positivo folicular 0-50 20.5 mo vs. 13.8 mo 6.7 mo mejora 64 vs66 0.0310 0.455
- Prior RX: 1
- CD68 Positivo folicular 0-50 18.2 mo vs. 9.3 mo 8.9 mo mejora 63 vs69 0.0129 0.447
- PSMB1/P11A C/G
- Tiempo desde último Rx: > 1 año 18.2 mo vs. 10.7 mo 7.5 mo mejora 72 vs74 0.0198 0.447
- Prior Ritutux NO
- CD68 Positivo folicular 0-50 15.9 mo vs. 9.2 mo 6.7 mo mejora 73 vs88 0.0066 0.437
- PSMB1/P11A C/G
- Grupo edad <=65 15.3 mo vs. 9.2 mo 6.1 mo mejora 86 vs96 0.0071 0.437
- Sexo Masculino
- 20S % TINCION NUCLEAR: >20 13.7 mo vs. 7.7 mo 6 mo mejora 63 vs48 0.0050 0.437
- Grupo carrera OTRO
- 20S % TINCION NUCLEAR: >20 11.4 mo vs. 3.8 mo 7.6 mo mejora 11 vs 7 0.0320 0.455
- PSMB1/P11A C/G
- PSMB5/R24C C/T 13.7 mo vs. 7.8 mo 5.9 mo mejora 7 vs. 7 0.0221 0.4468
Tabla 7 Pares marcadores significativos
- Combinación
- PFS Vc-R vs. R media meses Logrank Valor-p
- P65 Señal Citoplasmica >90% & 1
- 23.6 vs. 10.6 mo (13mo) 0.0132
- tratamiento anterior*
- 16 vs. 8.9 mo (7.1mo) n.s.
- CD68 Pos Folico (0-50) & P11A[C/G]**
- 14.2 vs 8.5 mo (5.7 mo) 0.0025
- 14.4 vs 9.2 mo (5.2 mo)
- n.s.
10 Arif A (2009), Jamal S, Mushtaq S, Ahmed S, Mubarik A. Frequency of bcl-2 gene rearrangement in B-Cell NonHodgkin’s lymphoma. Asian Pacific J Cancer Prev 2009; 10(2): 237-240.
Binstadt BA (2003), Geha RS, Bonilla FA. IgG Fc receptor polymorphisms in human disease: Implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol 2003; 111(4): 697-703.
15 Cartron G (2002), Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRllla gene. Blood 2002; 99(3): 754-758.
20 Chen P (1996), Hochstrasser M. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell 1996; 86: 961-972.
Chen S (2010), Blank JL, Peters T, Liu XJ, Rappoli DM, Pickard MD, Menon S, Driscoll DL, Lingaraj T, Burkhardt AL,
15
Apéndice 2, Tabla 2.2: OS variante genética de la línea germinal nd por covariable, revisión IRC (significativa [p≤0,05], frecuencia de ≥10 % o superior)
Vc-R Marcador: Subgrupo N
Marcador: Nivel Subgrupo HR (Escala log) R Media
Media total
3Lineas prioritarias de la terapita
Puntuación intermedia FLIPI
Ann Arbor Etapa IV
5
Apéndice 2, Tabla 2.3: OS por mutación somática y por covariable, revisión IRC (significativa [p≤0,05], frecuencia de ≥10 % o superior)
10 Marcador: Nivel Subgrupo HR ( Escala log) R Media Vc-R Media
2Lineas prioritarias de la terapia
No carga alta de tumor
15
Carga alta de tumor
Puntuacion FLIPI alta
Terapia no prior 20 Rituximab
Resto del Mundo
>65 Años de edad
25
Femenino
Masculino
30 Masculino
Masculino
Ann Arbor Etapa IV
35
40
45
50
20
Claims (1)
-
imagen1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161522596P | 2011-08-11 | 2011-08-11 | |
US201161522596P | 2011-08-11 | ||
US201161560555P | 2011-11-16 | 2011-11-16 | |
US201161560555P | 2011-11-16 | ||
PCT/US2012/049941 WO2013022935A1 (en) | 2011-08-11 | 2012-08-08 | Predictors for cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2586328T3 true ES2586328T3 (es) | 2016-10-13 |
Family
ID=47668910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12754124.1T Active ES2586328T3 (es) | 2011-08-11 | 2012-08-08 | Factores predisponentes para el tratamiento del cáncer |
Country Status (20)
Country | Link |
---|---|
US (1) | US9322066B2 (es) |
EP (1) | EP2742356B1 (es) |
JP (1) | JP6002222B2 (es) |
CN (1) | CN103930785B (es) |
AU (1) | AU2012294493B2 (es) |
CA (1) | CA2844825A1 (es) |
CY (1) | CY1117838T1 (es) |
DK (1) | DK2742356T3 (es) |
ES (1) | ES2586328T3 (es) |
HK (2) | HK1199094A1 (es) |
HR (1) | HRP20160851T1 (es) |
HU (1) | HUE029295T2 (es) |
MX (1) | MX357429B (es) |
PL (1) | PL2742356T3 (es) |
PT (1) | PT2742356E (es) |
RS (1) | RS55053B1 (es) |
RU (1) | RU2600026C2 (es) |
SI (1) | SI2742356T1 (es) |
SM (1) | SMT201600235B (es) |
WO (1) | WO2013022935A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10795879B2 (en) | 2012-06-22 | 2020-10-06 | Iqvia Inc. | Methods and systems for predictive clinical planning and design |
US20130342542A1 (en) * | 2012-06-22 | 2013-12-26 | Quintiles Transnational Corp. | Method and System To Manipulate Multiple Selections Against a Population of Elements |
US20170128518A1 (en) * | 2014-07-01 | 2017-05-11 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments |
JP6871851B2 (ja) * | 2014-09-10 | 2021-05-19 | リテンズ オートモーティヴ パートナーシップ | 捩りバネ力を使用する比例減衰式動力伝達デバイス |
CN109475600A (zh) * | 2016-06-17 | 2019-03-15 | 瓦里安医疗系统公司 | 免疫调节剂与辐射治疗组合 |
CN106874710A (zh) * | 2016-12-29 | 2017-06-20 | 安诺优达基因科技(北京)有限公司 | 一种用于利用肿瘤ffpe样本检测体细胞突变的装置 |
CN106845153A (zh) * | 2016-12-29 | 2017-06-13 | 安诺优达基因科技(北京)有限公司 | 一种用于利用循环肿瘤dna样本检测体细胞突变的装置 |
US11598403B2 (en) | 2017-03-28 | 2023-03-07 | Litens Automotive Partnership | Isolation device with selected angle between spring stop and damping member |
EP3705584A1 (en) | 2019-03-05 | 2020-09-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method of identifying patients with bortezomib resistant multiple myeloma and other blood diseases |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
US6096778A (en) | 1997-10-07 | 2000-08-01 | Cephalon, Inc. | α-ketoamide multicatalytic protease inhibitors |
US6075150A (en) | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
US6831099B1 (en) | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
ES2359391T3 (es) | 2001-01-25 | 2011-05-23 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Formulación de compuestos de acido boronico. |
AU2003298873B2 (en) | 2002-12-06 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
CN100366636C (zh) * | 2004-12-08 | 2008-02-06 | 中国农业科学院畜牧研究所 | 猪生产及免疫性状相关蛋白,它的编码基因与应用 |
KR100653990B1 (ko) | 2004-12-29 | 2006-12-05 | 주식회사 하이닉스반도체 | 포토마스크 데이터베이스 패턴의 불량 검사 방법 |
EP2687608B1 (en) | 2005-06-08 | 2017-02-08 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with cancer therapy |
US9500656B2 (en) | 2006-08-10 | 2016-11-22 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with cancer therapy |
WO2009148528A2 (en) | 2008-05-30 | 2009-12-10 | Millennium Pharmaceuticals, Inc. | Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment |
-
2012
- 2012-08-08 DK DK12754124.1T patent/DK2742356T3/en active
- 2012-08-08 AU AU2012294493A patent/AU2012294493B2/en not_active Ceased
- 2012-08-08 SI SI201230563A patent/SI2742356T1/sl unknown
- 2012-08-08 CN CN201280050089.1A patent/CN103930785B/zh not_active Expired - Fee Related
- 2012-08-08 EP EP12754124.1A patent/EP2742356B1/en active Active
- 2012-08-08 HU HUE12754124A patent/HUE029295T2/en unknown
- 2012-08-08 CA CA 2844825 patent/CA2844825A1/en not_active Abandoned
- 2012-08-08 RS RS20160589A patent/RS55053B1/sr unknown
- 2012-08-08 RU RU2014108986/15A patent/RU2600026C2/ru active
- 2012-08-08 WO PCT/US2012/049941 patent/WO2013022935A1/en active Application Filing
- 2012-08-08 PT PT127541241T patent/PT2742356E/pt unknown
- 2012-08-08 PL PL12754124.1T patent/PL2742356T3/pl unknown
- 2012-08-08 JP JP2014525107A patent/JP6002222B2/ja not_active Expired - Fee Related
- 2012-08-08 MX MX2014001619A patent/MX357429B/es active IP Right Grant
- 2012-08-08 US US13/569,517 patent/US9322066B2/en not_active Expired - Fee Related
- 2012-08-08 ES ES12754124.1T patent/ES2586328T3/es active Active
-
2014
- 2014-12-10 HK HK14112396.9A patent/HK1199094A1/xx not_active IP Right Cessation
- 2014-12-15 HK HK14112543.1A patent/HK1199097A1/zh not_active IP Right Cessation
-
2016
- 2016-07-12 HR HRP20160851TT patent/HRP20160851T1/hr unknown
- 2016-07-15 SM SM201600235T patent/SMT201600235B/it unknown
- 2016-07-26 CY CY20161100736T patent/CY1117838T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
RS55053B1 (sr) | 2016-12-30 |
US9322066B2 (en) | 2016-04-26 |
HK1199097A1 (zh) | 2015-06-19 |
EP2742356B1 (en) | 2016-04-27 |
HK1199094A1 (en) | 2015-06-19 |
EP2742356A1 (en) | 2014-06-18 |
US20130216524A1 (en) | 2013-08-22 |
SI2742356T1 (sl) | 2016-06-30 |
MX357429B (es) | 2018-07-09 |
MX2014001619A (es) | 2014-11-10 |
WO2013022935A1 (en) | 2013-02-14 |
CN103930785B (zh) | 2016-05-18 |
AU2012294493B2 (en) | 2017-02-23 |
PT2742356E (pt) | 2016-06-06 |
RU2600026C2 (ru) | 2016-10-20 |
HUE029295T2 (en) | 2017-02-28 |
CN103930785A (zh) | 2014-07-16 |
CY1117838T1 (el) | 2017-05-17 |
HRP20160851T1 (hr) | 2016-09-23 |
RU2014108986A (ru) | 2015-09-20 |
JP2014524571A (ja) | 2014-09-22 |
AU2012294493A1 (en) | 2014-02-20 |
JP6002222B2 (ja) | 2016-10-05 |
CA2844825A1 (en) | 2013-02-14 |
PL2742356T3 (pl) | 2016-11-30 |
DK2742356T3 (en) | 2016-05-23 |
SMT201600235B (it) | 2016-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2586328T3 (es) | Factores predisponentes para el tratamiento del cáncer | |
Lopez et al. | Plasmablastic lymphoma: current perspectives | |
Silvagni et al. | One year in review 2020: novelties in the treatment of rheumatoid arthritis | |
EP3458604B1 (en) | Method for determining sensitivity to a cdk4/6 inhibitor | |
d’Almeida et al. | The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: regulatory role of IL-27 | |
Madera et al. | Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3 | |
Chen et al. | Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma | |
Greenfield et al. | A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3 | |
Seo et al. | Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience | |
Lee et al. | Non-specific orbital inflammation: current understanding and unmet needs | |
WO2019178283A1 (en) | Methods and compositions for treating and prognosing colorectal cancer | |
JP6764790B2 (ja) | 視神経脊髄炎の治療に対する高可溶性アクアポリン−4細胞外ループペプチド免疫化 | |
van Hooij et al. | BCG-induced immunity profiles in household contacts of leprosy patients differentiate between protection and disease | |
US20210395722A1 (en) | TTF Generated Proliferation of Cytotoxic T Cells to Create a Specific Pro-Inflammatory Response | |
Ohmoto et al. | Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders | |
ES2351456A1 (es) | Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b. | |
Suzuki et al. | Clinical significance of cancer-related fatigue in multiple myeloma patients | |
US20220003770A1 (en) | Classification and Treatment of Gastric Cancer | |
Linquist et al. | Cytokine profiles in clinical subtypes of ophthalmic Graves’ disease | |
US10220016B2 (en) | Methods and materials for assessing chemotherapy responsiveness and treating cancer | |
CN107739758A (zh) | 一种RDH10基因用于制备TWEAK‑NF‑κB信号通路阻断剂的应用 | |
Mao et al. | PD-1 blockade-driven anti-tumor CD8+ T cell immunity requires XCR1+ dendritic cells | |
Sato et al. | Quantification of cytosolic DNA species by immunofluorescence microscopy and automated image analysis | |
US20230348599A1 (en) | Methods for treating glioblastoma | |
Alifu et al. | Distribution of HLA-A alleles and its relation to clinical outcome in Uyghur and Han patients with advanced squamous cell cervical cancer in Xinjiang, China |